Sarepta Therapeutics, Inc. (SRPT) research
Sarepta Therapeutics, Inc.- Sector
- Biotechnology
- Last price
- $17.50
- As of
Sarepta Therapeutics, Inc. (SRPT): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-23.
As of . Source: SEC EDGAR filings for SRPT. Method and limitations.
Share the SRPT intelligence card
See the full SRPT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SRPT on one page. Preview it with sample data, then open it live with a free account.
Preview the SRPT dossierActive signals for SRPT
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +1548% to SRPT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +202% to SRPT (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 92% of SRPT (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 119.0%, EPS $-0.05 vs $0.2625 estimate
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 85% of SRPT (2026Q1)
FREE, NO ACCOUNT
Every signal on SRPT, as it fires
You are seeing 5 of 13 signals recorded on SRPT since 2026-05-29.
The five above landed across 3 days. The other 8 were recorded on 1 other days. 8 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SRPT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 803607100 · 2026Q2 | $82.6M | 0.06% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 803607100 · 2026Q2 | $21.4M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 803607100 · 2026Q2 | $20.2M | 0.03% | , |
| D. E. Shaw & Co., Inc.CUSIP 803607AD2 · 2026Q2 | $15.9M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 803607100 · 2026Q2 | $9.2M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 803607100 · 2026Q2 | $2.7M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SRPT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SRPT against its peers
SRPT's operating margin of -37.5% ranks in the 58th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | SRPT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.9B USD | 90.3M USD | 97 | 16 |
| Operating margin | -37.5% | -113.7% | 58 | 17 |
| Net margin | -38.3% | -91.5% | 66 | 18 |
| Return on equity | -62.5% | -32.4% | 24 | 18 |
Peers (23): CMPS, SEPN, MESO, ZBIO, XNCR, NVAX, VIR, ZYME, LKFT, BHVN, RXRX, AGIO, NTLA, URGN, PVLA, NBTX, VCEL, STOK, FBRX, ABSI, AUPH, GHRS, BCRX. Left out: BRVE (no annual filing), GENB (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (SRPT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SRPT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SRPTand get the insider, 13F, options, and confluence read in one view.